Novartis | NVS - Cost Of Sales

Stock Price
156.42
Daily Change
2.62 1.70%
Monthly
10.22%
Yearly
47.28%
Q1 Forecast
145.07

Novartis reported $3.54B in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 2.8B 328M Sep/2025
Bausch Health Companies USD 750M 14M Sep/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Canopy Growth CAD 44.78M 9.32M Sep/2025
Corcept Therapeutics USD 4.6M 1.16M Sep/2025
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.57B 68M Sep/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Pacira USD 48.6M 6.59M Sep/2025
Perrigo USD 666.2M 27.2M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Prestige Brands USD 131.22M 3.52M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sanofi EUR 3.76B 344M Dec/2025
Supernus Pharmaceuticals USD 43.29M 5.64M Sep/2025
Zoetis USD 683M 3M Sep/2025